Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
The purpose of this study is to study a new treatment for HER2-positive breast cancer.
HER2-Positive Early Stage Breast Cancer
DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Lapatinib|DRUG: Pegfilgrastim
Number of Participants Who Are Able to Complete THL (Paclitaxel, Trastuzumab, and Lapatinib) Without a Dose Delay or Reduction, Grade 3 or Greater QTc Prolongation, The primary objective of this trial is to determine the feasibility of this regimen in patients with node-negative HER-2/neu overexpressed /amplified breast cancer with a tumor size of \< 3 cm. The regimen is considered feasible if patients are able to complete the paclitaxel, trastuzumab, and lapatinib (THL) portion of the regimen without a dose delay or reduction or grade 3 or greater QTc prolongation., 1 year
Participants Toxicity Evaluated While on Study Treatment, All toxicities following chemotherapy will be graded using the National Cancer Institute - Common Toxicity Criteria version 4.0., 1 year
The purpose of this study is to study a new treatment for HER2-positive breast cancer.